Skip to main content
. 2018 Aug 2;7(2):349–364. doi: 10.1007/s40120-018-0106-z

Table 2.

Patient health in the USA by ATTR amyloidosis type

Patients with ATTR-PN Patients with ATTR-CM Patients with both ATTR-PN and ATTR-CM
SF-12 Health Survey scorea, n 27 6 11
 Physical Health Summary 34.4 (11.7) 32.0 (9.5) 23.4 (7.3)
 Mental Health Summary 45.8 (10.1) 54.2 (8.6) 47.2 (11.2)
HADS score, n 27 6 11
 Depression subscale 6.2 (3.2) 6.0 (3.5) 6.1 (2.0)
 Anxiety subscale 6.1 (4.1) 4.2 (4.1) 5.5 (3.3)
Pain, n 27 6 11
 Pain, right now 3.6 (3.2) 0.8 (2.0) 2.6 (1.4)
 Average pain, past week 3.6 (3.1) 0.8 (1.6) 3.0 (1.6)
 Worst pain, past week 4.7 (3.4) 1.2 (1.8) 5.0 (2.8)
EQ-5D-3L health survey, n 27 6 11
 Mobility 1.7 (0.5) 1.7 (0.5) 1.9 (0.3)
 Self-care 1.3 (0.5) 1.0 (0.0) (NA) 1.5 (0.7)
 Usual activities 2.0 (0.5) 1.7 (0.8) 2.3 (0.6)
 Pain/discomfort 1.8 (0.6) 1.3 (0.5) 1.8 (0.4)
 Anxiety/depression 1.5 (0.5) 1.2 (0.4) 1.3 (0.5)
 Utility index score 0.71 (0.2) 0.83 (0.2) 0.66 (0.2)
 Overall health status rating 59.6 (20.7) 63.2 (12.7) 46.2 (19.8)
Kansas City cardiomyopathy score, n 6 11 17
 Physical limitation 61.1 (26.1) 31.1 (25.9) 41.7 (29.2)
 Symptom stability 54.2 (10.2) 45.5 (10.1) 48.5 (10.7)
 Symptom frequency 65.6 (21.9) 37.9 (21.6) 47.7 (25.1)
 Symptom burden 68.1 (23.8) 41.7 (20.1) 51.0 (24.5)
 Total symptom 66.8 (22.5) 39.8 (19.3) 49.3 (23.8)
 Self-efficacy 81.3 (20.5) 77.3 (22.2) 78.7 (21.1)
 Quality of life 57.0 (23.8) 46.2 (15.1) 50.0 (18.6)
 Social limitation 44.8 (27.8) 24.6 (21.4) 31.8 (25.0)
 Overall summary 57.4 (18.9) 35.4 (16.5) 43.2 (20.0)
 Clinical summary 64.0 (23.8) 35.4 (20.3) 45.5 (25.2)

All assessment scores are mean (standard deviation) unless otherwise indicated

EQ-5D-3L EuroQol–5 Dimensions–3 Levels questionnaire, HADS Hospital Anxiety and Depression Scale, NA not available, SF-12 12-Item Short Form Health Survey (version 2)

aThe 1-week recall version of the SF-12 form was used in Spain and the 4-week recall version was used in the USA